良性前列腺增生治疗器材市场－全球产业规模、份额、趋势、机会及预测（依治疗方法、手术、产品、最终用途、地区及竞争格局划分），2021-2031年

全球良性前列腺增生治疗器材市场预计将从2025年的130.6亿美元成长至2031年的172.1亿美元，复合年增长率（CAGR）为4.71%。该市场涵盖多种微创和外科手术技术，例如雷射消熔系统、电外科器械和前列腺尿道提升植入，所有这些技术都旨在缓解非恶性前列腺增生引起的下泌尿道症状。推动市场成长的关键因素是男性人口的快速老化以及临床上对微创疗法（相比传统手术恢復时间更短）的强烈偏好，这确保了市场需求的持续稳定，不受暂时趋势的影响。

然而，该市场面临着许多障碍，例如针对新型医疗设备技术的复杂报销体系，这往往限制了预算紧张的医疗保健系统中患者获得和使用此类技术的机会。美国泌尿系统协会的报告凸显了这个问题的严重性：到2024年，65岁及以上男性良性前列腺增生的盛行率将达到29%至35%。如此高的盛行率凸显了该领域对便捷治疗方案日益增长的需求和重要性。

市场驱动因素

机器人辅助系统和雷射消熔技术的创新正在改变市场格局，其重点在于提高手术精准度和加快术后恢復速度。这些进步正迅速取代传统的经尿道切除术，临床医生和患者都越来越倾向于选择自动化、组织保留性手术技术，以减少性功能障碍和住院时间。新兴市场领导的财务成功也反映了这一转变；例如，PROCEPT BioRobotics公司公布的2024年第三季财报显示，其营收年增66%，达到5,840万美元，这主要得益于其Aquablation机器人系统的强劲应用。

此外，由于老化与摄护腺增生密切相关，全球老年人口的成长是推动市场长期成长的关键人口因素。随着预期寿命的延长，越来越多的男性出现下泌尿道症状，催生了对可扩展医疗解决方案的需求。根据联合国人口基金会发布的《2024年世界人口展望》，到2024年，65岁及以上人口将占世界人口的10.3%，显示患者群体结构发生了显着变化。这一人口趋势正在创造商业性机会，波士顿科学公司2025年2月发布的报告也证实，其泌尿系统部门在2024财年的全年净销售额将增长12.0%，进一步印证了老年人口日益增长的需求。

市场挑战

全球良性前列腺增生治疗器材市场的成长受到创新技术复杂报销环境的显着阻碍，这对医疗机构造成了财务障碍。新器材经常在缺乏既定计费代码或有利的保险覆盖范围的情况下上市，迫使医疗机构自行承担成本或适应难以预测的付款模式。这种财务上的不确定性阻碍了医院和泌尿系统诊所购买昂贵的器械，导致他们优先选择已建立且可全额报销的成熟疗法，而不是更新、可能更有益的治疗方案。

因此，泌尿系统的利润空间正在缩小，进一步限制了新兴治疗方法的应用范围。根据美国泌尿系统协会 (AUA) 2024 年的报告，美国医疗保险和医疗补助服务中心 (CMS) 最终确定了支付规则，将在下一财政年度将医疗保险转换係数降低约 2.83%。报销率的降低严重加重了医疗服务提供者的经济负担，直接限制了他们采用新型设备治疗良性前列腺增生 (BPH) 的能力，并在註重成本的医疗环境中抑制了整体市场成长。

市场趋势

临时性镍钛合金植入装置的引入标誌着前列腺尿道非永久性机械再形成治疗方式的重要转变，使其区别于永久性支架和消融疗法。诸如iTind系统之类的装置旨在再形成膀胱颈，同时避免热损伤和永久性植入，从而保留性功能，并解决患者对生活品质的重要关切。随着製造商向关键地区扩张，这种创新方法正获得商业性发展动力。例如，Olympus Corporation在2024年8月报告称，2025财年第一季北美销售额年增32%，这一业绩部分归功于iTind装置的战略市场部署。

同时，水蒸气热疗的广泛商业化应用，利用对流蒸气能量有效治疗增生，为门诊手术树立了新的标准。与机器人手术或雷射剜除术不同，该技术将无菌水蒸气输送至前列腺组织，迅速释放热能导致细胞死亡，无需大规模的手术设备。这项技术因其能在短时间内提供持久的症状缓解而迅速普及，推动了主要医疗设备製造商的成长。波士顿科学公司于2024年10月发布的「2024财年第三季业绩报告」显示，泌尿系统净销售额成长10.3%，这主要得益于其前列腺健康业务（包括Rezum水蒸气治疗系统）的两位数成长。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 良性摄护腺增生治疗器材的全球市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依治疗方法（微创手术、侵入性手术）
  • 依手术方式（经经尿道前列腺切除术、摄护腺雷射手术、经尿道微波热疗、经尿道摄护腺针消融术、摄护腺尿道提升、水蒸气治疗、其他）
  • 依产品分类（电切镜、泌尿系统雷射、射频消融术、电极、导管、摄护腺支架、植入、其他）
  • 按用途（医院/诊所、研究/製造、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美良性摄护腺增生治疗器材市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

7. 欧洲良性前列腺增生治疗设备市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章 亚太地区良性摄护腺增生治疗设备市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲良性前列腺增生治疗设备市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲良性摄护腺增生治疗器材市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球良性前列腺增生治疗设备市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Boston Scientific Corporation
• Olympus America
• Endo Pharmaceuticals Inc.
• biolitec AG
• Medifocus Inc.
• Cook Medical
• Teleflex Incorporated
• Urotronic
• Coloplast Corp
• Richard Wolf GmbH
• PROCEPT BioRobotics Corporation

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Benign Prostatic Hyperplasia Treatment Devices Market is projected to expand from USD 13.06 Billion in 2025 to USD 17.21 Billion by 2031, registering a CAGR of 4.71%. This market includes a variety of minimally invasive and surgical technologies, such as laser ablation systems, electrosurgical units, and prostatic urethral lift implants, all aiming to relieve lower urinary tract symptoms caused by non-malignant prostate enlargement. Growth is largely driven by a rapidly aging male population and a strong clinical preference for minimally invasive therapies that allow for faster recovery compared to traditional surgeries, ensuring lasting demand independent of fleeting trends.

However, the market faces a significant obstacle in the form of complex reimbursement structures for new device technologies, which often limit patient access and adoption within budget-conscious healthcare systems. Highlighting the magnitude of this issue, the American Urological Association reported in 2024 that the prevalence of Benign Prostatic Hyperplasia in men aged 65 and older ranged between 29% and 35%. This high prevalence reinforces the critical and increasing need for accessible therapeutic options within the sector.

Market Driver

Technological innovations in robotic-assisted systems and laser ablation are transforming the market by emphasizing precision and faster recovery times. These advancements are rapidly replacing traditional transurethral resections as both clinicians and patients favor automated, tissue-sparing methods that reduce sexual side effects and hospital stays. The financial success of emerging market leaders reflects this shift; for instance, PROCEPT BioRobotics reported a 66% year-over-year revenue increase to $58.4 million in its Third Quarter 2024 Financial Results, driven largely by the strong adoption of its Aquablation robotic systems.

Additionally, the growing global geriatric population serves as a major demographic driver for long-term market growth, due to the link between aging and prostate enlargement. As life expectancy rises, the number of men developing lower urinary tract symptoms increases, creating a need for scalable medical solutions. The United Nations Population Fund's '2024 State of World Population Report' noted that those aged 65 and older constituted 10.3% of the global population in 2024, indicating a major shift in patient density. This demographic trend creates commercial opportunities, as seen in Boston Scientific's February 2025 report, where the Urology segment saw a 12.0% rise in full-year 2024 net sales, confirming rising demand among the elderly.

Market Challenge

The growth of the Global Benign Prostatic Hyperplasia Treatment Devices Market is significantly hindered by a complicated reimbursement environment for innovative technologies, which creates financial hurdles for healthcare providers. New devices frequently launch without established billing codes or favorable insurance coverage, compelling medical facilities to either absorb the costs or navigate unpredictable payment models. This financial uncertainty deters hospitals and urology practices from purchasing expensive equipment, leading them to prefer established, fully reimbursed procedures over newer, potentially more beneficial alternatives.

As a result, urologists experience shrinking profit margins that further limit their capacity to incorporate emerging therapies. According to the American Urological Association in 2024, the Centers for Medicare & Medicaid Services finalized a payment rule reducing the Medicare conversion factor by approximately 2.83 percent for the following year. This cut in reimbursement rates intensifies financial strain on providers, directly restricting their ability to adopt novel BPH treatment devices and impeding overall market growth in cost-sensitive healthcare settings.

Market Trends

The introduction of temporary implantable nitinol devices marks a significant shift toward non-permanent, mechanical reshaping of the prostatic urethra, distinguishing these tools from permanent stents or ablative techniques. Devices such as the iTind system are engineered to remodel the bladder neck while preserving sexual function by avoiding thermal injury or permanent implants, thereby addressing a key quality-of-life concern for patients. This innovative method is gaining commercial momentum as manufacturers expand into key regions; for example, Olympus Corporation reported in August 2024 that its North American revenue rose by 32% year-over-year in the first quarter of fiscal year 2025, a result partly linked to the strategic market development of its iTind device.

Simultaneously, the broad commercialization of water vapor thermal therapy is setting a new benchmark for office-based procedures by using convective steam energy to treat hyperplasia effectively. Unlike robotic or laser enucleation, this modality delivers sterile water vapor into prostate tissue, rapidly dispersing thermal energy to cause cell death without requiring extensive surgical infrastructure. The technology's rapid adoption is driven by its ability to provide lasting symptom relief with short procedure times, contributing to growth for major device companies; Boston Scientific's 'Third Quarter 2024 Financial Results' in October 2024 showed a 10.3% increase in Urology net sales, bolstered by double-digit growth in its prostate health franchise, including the Rezum Water Vapor Therapy system.

Key Market Players

• Boston Scientific Corporation
• Olympus America
• Endo Pharmaceuticals Inc.
• biolitec AG
• Medifocus Inc.
• Cook Medical
• Teleflex Incorporated
• Urotronic
• Coloplast Corp
• Richard Wolf GmbH
• PROCEPT BioRobotics Corporation

Report Scope

In this report, the Global Benign Prostatic Hyperplasia Treatment Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Benign Prostatic Hyperplasia Treatment Devices Market, By Treatment

• Minimal Invasive Surgery
• Invasive Surgery

Benign Prostatic Hyperplasia Treatment Devices Market, By Procedure

• Transurethral Resection of the Prostate
• Prostate Laser Surgery
• Transurethral Microwave Thermotherapy
• Transurethral Needle Ablation of the Prostate
• Prostatic Urethral Lift
• Water Vapor Therapy
• Others

Benign Prostatic Hyperplasia Treatment Devices Market, By Product

• Resectoscopes
• Urology Laser
• Radiofrequency Ablation
• Electrodes
• Catheters
• Prostatic Stents
• Implants
• Others

Benign Prostatic Hyperplasia Treatment Devices Market, By End use

• Hospitals & Clinics
• Research and Manufacturing
• others

Benign Prostatic Hyperplasia Treatment Devices Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Benign Prostatic Hyperplasia Treatment Devices Market.

Available Customizations:

Global Benign Prostatic Hyperplasia Treatment Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Benign Prostatic Hyperplasia Treatment Devices Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Minimal Invasive Surgery, Invasive Surgery)
  • 5.2.2. By Procedure (Transurethral Resection of the Prostate, Prostate Laser Surgery, Transurethral Microwave Thermotherapy, Transurethral Needle Ablation of the Prostate, Prostatic Urethral Lift, Water Vapor Therapy, Others)
  • 5.2.3. By Product (Resectoscopes, Urology Laser, Radiofrequency Ablation, Electrodes, Catheters, Prostatic Stents, Implants, Others)
  • 5.2.4. By End use (Hospitals & Clinics, Research and Manufacturing, others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Benign Prostatic Hyperplasia Treatment Devices Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Procedure
  • 6.2.3. By Product
  • 6.2.4. By End use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Procedure
      • 6.3.1.2.3. By Product
      • 6.3.1.2.4. By End use
  • 6.3.2. Canada Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Procedure
      • 6.3.2.2.3. By Product
      • 6.3.2.2.4. By End use
  • 6.3.3. Mexico Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Procedure
      • 6.3.3.2.3. By Product
      • 6.3.3.2.4. By End use

7. Europe Benign Prostatic Hyperplasia Treatment Devices Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Procedure
  • 7.2.3. By Product
  • 7.2.4. By End use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Procedure
      • 7.3.1.2.3. By Product
      • 7.3.1.2.4. By End use
  • 7.3.2. France Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Procedure
      • 7.3.2.2.3. By Product
      • 7.3.2.2.4. By End use
  • 7.3.3. United Kingdom Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Procedure
      • 7.3.3.2.3. By Product
      • 7.3.3.2.4. By End use
  • 7.3.4. Italy Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By Procedure
      • 7.3.4.2.3. By Product
      • 7.3.4.2.4. By End use
  • 7.3.5. Spain Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By Procedure
      • 7.3.5.2.3. By Product
      • 7.3.5.2.4. By End use

8. Asia Pacific Benign Prostatic Hyperplasia Treatment Devices Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Procedure
  • 8.2.3. By Product
  • 8.2.4. By End use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Procedure
      • 8.3.1.2.3. By Product
      • 8.3.1.2.4. By End use
  • 8.3.2. India Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Procedure
      • 8.3.2.2.3. By Product
      • 8.3.2.2.4. By End use
  • 8.3.3. Japan Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Procedure
      • 8.3.3.2.3. By Product
      • 8.3.3.2.4. By End use
  • 8.3.4. South Korea Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By Procedure
      • 8.3.4.2.3. By Product
      • 8.3.4.2.4. By End use
  • 8.3.5. Australia Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By Procedure
      • 8.3.5.2.3. By Product
      • 8.3.5.2.4. By End use

9. Middle East & Africa Benign Prostatic Hyperplasia Treatment Devices Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Procedure
  • 9.2.3. By Product
  • 9.2.4. By End use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Procedure
      • 9.3.1.2.3. By Product
      • 9.3.1.2.4. By End use
  • 9.3.2. UAE Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Procedure
      • 9.3.2.2.3. By Product
      • 9.3.2.2.4. By End use
  • 9.3.3. South Africa Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Procedure
      • 9.3.3.2.3. By Product
      • 9.3.3.2.4. By End use

10. South America Benign Prostatic Hyperplasia Treatment Devices Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By Procedure
  • 10.2.3. By Product
  • 10.2.4. By End use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By Procedure
      • 10.3.1.2.3. By Product
      • 10.3.1.2.4. By End use
  • 10.3.2. Colombia Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By Procedure
      • 10.3.2.2.3. By Product
      • 10.3.2.2.4. By End use
  • 10.3.3. Argentina Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By Procedure
      • 10.3.3.2.3. By Product
      • 10.3.3.2.4. By End use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Benign Prostatic Hyperplasia Treatment Devices Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Boston Scientific Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Olympus America
• 15.3. Endo Pharmaceuticals Inc.
• 15.4. biolitec AG
• 15.5. Medifocus Inc.
• 15.6. Cook Medical
• 15.7. Teleflex Incorporated
• 15.8. Urotronic
• 15.9. Coloplast Corp
• 15.10. Richard Wolf GmbH
• 15.11. PROCEPT BioRobotics Corporation

16. Strategic Recommendations

17. About Us & Disclaimer